Ras signaling is frequently activated in human breast cancer, usually not by mutations in a Ras gene per se, but by mutations and overexpression of upstream signaling components such as receptor tyrosine kinases and NF1 mutations (121). This evidence concerns the gene NF1 and breast cancer.